Guanylyl cyclase Inhibitors
2 drugsAbout Guanylyl cyclase
Guanylyl cyclase (GC) enzymes are receptors that catalyze cyclic GMP (cGMP) production, a second messenger involved in various physiological processes like vasodilation and smooth muscle relaxation.
Guanylyl cyclase's role in regulating vasodilation makes it a valuable cardiovascular drug target, though no direct genetic evidence currently links it to specific diseases.
Two approved drugs target guanylyl cyclase: BIDIL and ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, both small molecules for cardiovascular applications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Basal Cell Carcinoma with only 1 trials.
Top Guanylyl cyclase Drugs
The competitive landscape includes two companies with approved drugs: AZURITY and INGENUS PHARMS LLC.
Low market concentration suggests opportunities for new entrants, but also potential pricing pressure.
Guanylyl cyclase Drug Modality Landscape
Modalities
Routes of Administration
Guanylyl cyclase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like biologics to differentiate from existing small molecule drugs.
Guanylyl cyclase Clinical Trials 14 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 5 | 5 | 0 | 0 | 100% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Guanylyl cyclase Drug Approval Timeline (2005 - 2022)
The first drug was approved in 2005 (BIDIL), with the most recent in 2022.
The approval timeline indicates continued interest, but also suggests potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 18 clinical trials targeting Guanylyl cyclase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities